Adam M, Bekuretsion Y, Gebremedhin A, Kwiecinska A, Howe R, Petros B
J Clin Exp Hematop. 2023; 63(4):230-239.
PMID: 38148013
PMC: 10861371.
DOI: 10.3960/jslrt.23037.
Tonnelet D, Bohn M, Becker S, Decazes P, Camus V, Thureau S
EJNMMI Res. 2021; 11(1):37.
PMID: 33846870
PMC: 8041962.
DOI: 10.1186/s13550-021-00776-9.
Ferrarini I, Rigo A, Visco C, Krampera M, Vinante F
Cancers (Basel). 2020; 12(12).
PMID: 33327433
PMC: 7764890.
DOI: 10.3390/cancers12123757.
Goncharova O, Flinner N, Bein J, Doring C, Donnadieu E, Rikirsch S
Cancers (Basel). 2019; 11(10).
PMID: 31581676
PMC: 6827161.
DOI: 10.3390/cancers11101484.
Aldinucci D, Borghese C, Casagrande N
Int J Mol Sci. 2019; 20(10).
PMID: 31096713
PMC: 6566335.
DOI: 10.3390/ijms20102416.
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.
van der Weyden C, Pileri S, Feldman A, Whisstock J, Prince H
Blood Cancer J. 2017; 7(9):e603.
PMID: 28885612
PMC: 5709754.
DOI: 10.1038/bcj.2017.85.
Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.
Levin L, Breen E, Birmann B, Batista J, Magpantay L, Li Y
Cancer Epidemiol Biomarkers Prev. 2017; 26(7):1114-1123.
PMID: 28341757
PMC: 5511544.
DOI: 10.1158/1055-9965.EPI-16-1012.
Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma.
Visser L, Rutgers B, Diepstra A, van den Berg A, Sattarzadeh A
Int J Mol Sci. 2016; 17(12).
PMID: 27999289
PMC: 5187927.
DOI: 10.3390/ijms17122127.
Classical Hodgkin Lymphoma with Positive Epstein-Barr Virus Status is Associated with More FOXP3 Regulatory T Cells.
Pavlovic A, Glavina Durdov M, capkun V, Jakelic Pitesa J, Bozic Sakic M
Med Sci Monit. 2016; 22:2340-6.
PMID: 27377121
PMC: 4946389.
DOI: 10.12659/msm.896629.
An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack.
Jahn T, Zuther M, Friedrichs B, Heuser C, Guhlke S, Abken H
PLoS One. 2012; 7(9):e44482.
PMID: 23028547
PMC: 3445545.
DOI: 10.1371/journal.pone.0044482.
Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma.
Plattel W, van den Berg A, Visser L, van der Graaf A, Pruim J, Vos H
Haematologica. 2011; 97(3):410-5.
PMID: 22058214
PMC: 3291596.
DOI: 10.3324/haematol.2011.053199.
Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs.
Hong B, Peng G, Berry L, Gottschalk S, Jung J, Chen S
Gene Ther. 2011; 19(8):818-27.
PMID: 22052242
PMC: 3288357.
DOI: 10.1038/gt.2011.160.
T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.
Fozza C, Longinotti M
Adv Hematol. 2010; 2011:501659.
PMID: 20975771
PMC: 2957104.
DOI: 10.1155/2011/501659.
Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.
De J, Brown R
Int J Clin Exp Med. 2010; 3(1):55-68.
PMID: 20369041
PMC: 2848307.
The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma.
Koreishi A, Saenz A, Persky D, Cui H, Moskowitz A, Moskowitz C
Appl Immunohistochem Mol Morphol. 2010; 18(3):206-11.
PMID: 20065852
PMC: 3260943.
DOI: 10.1097/PAI.0b013e3181c7138b.
Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma.
Birgersdotter A, Baumforth K, Porwit A, Sjoberg J, Wei W, Bjorkholm M
Br J Cancer. 2009; 101(8):1393-401.
PMID: 19773754
PMC: 2768440.
DOI: 10.1038/sj.bjc.6605238.
Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.
Biggar R, Johansen J, Smedby K, Rostgaard K, Chang E, Adami H
Clin Cancer Res. 2008; 14(21):6974-8.
PMID: 18980992
PMC: 2613488.
DOI: 10.1158/1078-0432.CCR-08-1026.
Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder.
Takegawa S, Jin Z, Nakayama T, Oyama T, Hieshima K, Nagakubo D
Cancer Sci. 2008; 99(2):296-302.
PMID: 18271928
PMC: 11158311.
DOI: 10.1111/j.1349-7006.2007.00687.x.
Immunotherapies for Hodgkin's lymphoma.
Kasamon Y, Ambinder R
Crit Rev Oncol Hematol. 2007; 66(2):135-44.
PMID: 18023356
PMC: 5792053.
DOI: 10.1016/j.critrevonc.2007.10.001.
Hodgkin's lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments.
Atayar C, van den Berg A, Blokzijl T, Boot M, Gascoyne R, Visser L
J Clin Pathol. 2006; 60(10):1092-7.
PMID: 17158640
PMC: 2014845.
DOI: 10.1136/jcp.2006.044222.